ArticleOncology reports2019

[Corrigendum] Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models.

Ronald A Lubet et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.